JF
ATNM icon

Jump Financial’s Actinium Pharmaceuticals ATNM Stock Holding History

Jump Financial’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-16,700
Closed -$124K – 1839
2023
Q2 		$124K Buy
16,700
+3,608
+28% +$30.7K ﹤0.01% 1620
2023
Q1 		$124K Sell
13,092
-10,621
-45% -$112K 0.01% 1410
2022
Q4 		$253K Buy
23,713
+313
+1% +$3.18K 0.01% 1146
2022
Q3 		$173K Buy
+23,400
New +$145K 0.01% 1375

Other funds holding ATNM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jump Financial's ATNM Position: Q3 2023 in Review

Jump Financial sold out of Actinium Pharmaceuticals (ATNM) in Q3 2023, closing a stake of 16,700 shares — an estimated $124K sold.

Jump Financial first reported a position in ATNM in Q3 2022 and held it in 4 quarters. The position peaked at $253K in Q4 2022. 58 funds tracked by Wall St. Rank hold ATNM as of Q3 2023.

  • Jump Financial reported no remaining Actinium Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Jump Financial sold 16,700 Actinium Pharmaceuticals shares in Q3 2023, an estimated $124K.
  • Jump Financial first reported a position in Actinium Pharmaceuticals in Q3 2022 and held it in 4 quarters.
  • Jump Financial's Actinium Pharmaceuticals position peaked at $253K in Q4 2022.
  • 58 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2023.

Based on Jump Financial's 13F filing for Q3 2023, filed 7 Nov 2023.